Kiadis Pharma celebrates IPO by sounding gong
By sounding the gong, Kiadis Pharma celebrates its IPO on Euronext Amsterdam and Euronext Brussels. CEO of Kiadis Pharma, Manfred Rüdiger, sounds the gong to open trading.
Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders.
Rüdiger: “We are delighted to have joined Euronext today. Kiadis Pharma's IPO received significant interest from local, European and US investors and now we intend to advance our pipeline of products that will potentially save the lives of thousands of blood cancer and inherited blood disorder patients.”
For more information: www.kiadis.com